GTx: Phase 2 ASTRID Trial With Enobosarm Fails To Achieve Its Primary Endpoint

(RTTNews) - GTx, Inc. (GTXI) announced the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm in post-menopausal women with stress urinary incontinence, did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% reduction in incontinence episodes per day compared to placebo. Enobosarm was generally safe and well tolerated.

Robert Wills, Executive Chairman of GTx, said: "We plan to conduct a full review of all the data. We have an ongoing preclinical program assessing the potential of SARDs, our novel selective androgen receptor degrader technology, to treat castration-resistant prostate cancer. We are currently on target to have development candidates by year end, which we potentially plan to take into IND-enabling studies."